John G. Curd

CollabRx uses information technology to inform personalized cancer treatment planning by combining the world's knowledge on cutting-edge therapies with specific insights from the nation's top cancer experts starting with the area of greatest need advanced cancers in patients who have effectively exhausted the standard of care. For physicians, Collabrx provides sophisticated, yet intuitive decision support tools to help them rapidly and accurately determine which medical tests, therapies, and clinical trials should be considered in order to deliver the best possible care to their patients. For patients, CollabRx provides actionable and highly-credible information that can be shared with their oncologist in a form that supports collaborative decision making in determining a cancer treatment plan that is customized for them. For researchers, CollabRx provides a framework to categorize the molecular subtypes of cancer based on the genetic profile of the tumor, and more importantly link specific subtypes to relevant treatments and ultimately patient clinical outcomes to drive the science and medicine forward.

Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA

Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA.

Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA.

VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA.

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.